Abbott Cuts 2026 Sales Growth Forecast
The healthcare company lowered its full-year revenue outlook to about 6% after weaker heart-device sales and nutrition-business pressures.
Updated on Nov. 10, 2026 in Healthcare

Abbott Laboratories cut its 2026 sales-growth forecast to about 6% from 6.5%-7.5%, and its shares fell 1.9% on Oct. 21. The company's Q3 2026 adjusted EPS of $1.42 matched estimates, while revenue of $13.01 billion slightly exceeded consensus.
Why it matters
Medical-device revenue missed expectations mainly due to weaker-than-expected heart-device sales, and the nutrition business faced pressure from the loss of a major U.S. government supply contract, higher manufacturing costs, weaker demand and costly litigation. The shortfall weighs on investors as Abbott's stock has trailed the broader market.
Abbott's market capitalization stands at $190.2 billion, and its stock has fallen 12.5% over the past 52 weeks while the S&P 500 gained 12.2%. Analysts expect adjusted EPS to grow 7.2% year over year to $5.52 for fiscal 2026, though the size of the infant formula litigation exposure has not been quantified.
The players
Abbott Laboratories
A global healthcare company headquartered in Abbott Park, Illinois, that makes medical devices, nutrition products and diagnostics.
Travis Steed
A Bank of America analyst who raised his price target on Abbott to $125 and maintained a Buy rating.
The details
Abbott lowered its 2026 sales-growth outlook after medical-device revenue fell short due to weaker heart-device sales and its nutrition division struggled with the loss of a major U.S. government supply contract. The company also plans to spin off its nutrition division in 2027.
Timeline
Oct. 21: Abbott shares fell 1.9% following the forecast cut.
Q3 2026: Adjusted EPS of $1.42 matched estimates and revenue reached $13.01 billion.
Nov. 9: BofA analyst Travis Steed raised the price target to $125 and kept a Buy rating.
2027: Abbott plans to spin off its nutrition division.
Market Landscape
Abbott's 12.5% decline over 52 weeks contrasts with the State Street Health Care Select Sector SPDR ETF's 28.9% return, signaling that the company has lagged its own sector as well as the S&P 500. The gap places Abbott among healthcare names that have struggled to convert sector strength into shareholder returns.
Investors holding Abbott shares face a stock that has trailed both the S&P 500 and its healthcare sector peers over the past year. Analyst price targets averaging $118.42 imply a modest premium to current levels, though the outcome depends on whether nutrition and device sales recover.
The takeaway
Revenue that meets expectations can still sink a stock when guidance is trimmed and business segments face headwinds. Watching segment-level results, not just headline EPS, reveals where a company's growth is really coming from.
Further reading
Explore more Healthcare coverage for context on the sector Abbott operates in.
Source note: This article includes information reported by Barchart.






